POET Technologies Shares Surge 71.57% Amid Positive Market Sentiment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy POET?
Source: Benzinga
- Positive Market Sentiment: POET Technologies shares surged 7.17% to $8.66 on Thursday, reflecting strong overall market performance with the Nasdaq up 0.97% and the tech sector gaining 1.52%, providing a favorable environment for the company's future growth.
- Long-Term Growth Potential: Over the past 12 months, POET's stock has increased by 71.57%, indicating strong long-term growth potential, with analysts expressing optimism about the company's future, as reflected in recent rating upgrades.
- Strong Technical Indicators: Currently, POET is trading 23.7% above its 20-day simple moving average and 39.4% above its 100-day SMA, demonstrating solid short-term and long-term strength, while being closer to its 52-week highs, suggesting bullish sentiment among traders.
- Optimistic Analyst Ratings: The average price target for POET is $5.83, with analysts generally rating it as a “Buy”; Northland Capital Markets raised its target to $7.00, reflecting confidence in the company's future profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POET?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POET
About POET
POET Technologies Inc. is a design and development company. It offers high-speed optical engines, light source products and custom optical modules to the artificial intelligence (AI) systems market and to hyperscale data centers. Its photonic integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. Its Optical Interposer-based products consume less power than comparable products, are smaller in size and are readily scalable to high production volumes. In addition, it has designed and produced novel light source products for chip-to-chip data communication within and between AI servers, the next frontier for solving bandwidth and latency problems in AI systems. Its Optical Interposer platform solves device integration challenges across a range of communication, computing and sensing applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Poet Technologies Issues 20.7 Million Shares to Raise $150 Million, Stock Plummets 17%
- Capital Raising Announcement: Poet Technologies revealed plans to issue 20.7 million shares, aiming to raise approximately $150 million, which led to a 17% drop in stock price, indicating strong market discontent with the financing effort.
- Significant Stock Impact: The share price is set at about $7.25, resulting in a market cap reduction to approximately $759 million, reflecting investor concerns over dilution of existing shares.
- Clear Use of Proceeds: The company intends to allocate the raised funds to enhance research and development as well as the development of high-speed optical modules and light sources, particularly for applications in artificial intelligence infrastructure, demonstrating its focus on future market opportunities.
- Market Reaction Analysis: Although the financing may dilute shares, analysts believe that investing in AI technology holds substantial potential, possibly presenting a buying opportunity for long-term investors in Poet as the sector continues to grow.
See More
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
See More
Poet Technologies Plans $150 Million Offering to Accelerate R&D and Acquisitions
- Clear Use of Proceeds: Poet Technologies plans to utilize the $150 million from its registered direct offering for targeted acquisitions, scaling up R&D, and accelerating its high-speed optical module and light source businesses, aiming to enhance overall operational capacity and market competitiveness.
- Offering Details Disclosed: The company will sell over 20 million common shares to institutional investors, with the offering expected to close around January 23, 2026, reflecting confidence in future growth prospects.
- Mixed Market Reaction: Despite a more than 13% drop in POET's stock price following the announcement, retail sentiment on Stocktwits remains 'extremely bullish', with investors believing the offering will strengthen the company's cash flow and market position.
- Potential Risk Warning: Some users caution that the offering may lead to share dilution, noting that POET's stock fell by 50% after the last issuance, prompting investors to carefully assess the associated risks and rewards.
See More
POET Technologies Announces Direct Offering of 20.7M Shares, Expected to Raise $150M
- Funding Plan: POET Technologies has entered into securities purchase agreements with institutional investors to sell 20,689,656 common shares, expected to raise approximately $150 million, which will be utilized for corporate development and targeted acquisitions to enhance R&D capabilities.
- Market Reaction: Despite the Nasdaq gaining 1.01%, POET's stock fell 7.77% to $7.72, indicating a negative market response to the offering news, which may impact short-term investor confidence.
- Technical Indicators: The stock is currently trading 4.2% above its 20-day simple moving average and 22% above its 100-day moving average, indicating a strong long-term trend, with shares up 53.58% over the past 12 months, approaching 52-week highs.
- Earnings Expectations: Investors are looking forward to the upcoming earnings report, with an EPS estimate of a loss of 6 cents (an improvement from a loss of 48 cents YoY) and a revenue estimate of $0.62 million (up from $0.03 million YoY), indicating potential for earnings improvement.
See More
POET Technologies Prices $150M Direct Offering Amid 3.11% Pre-Market Drop
- Offering Size: POET Technologies announced a registered direct offering priced at $150 million, involving 20,689,656 shares of common stock, highlighting the company's ability to raise capital in the market.
- Investor Agreements: The company has entered into securities purchase agreements with institutional investors, with the offering expected to close around January 23, 2026, providing essential funding for future growth.
- Use of Proceeds: The net proceeds from this offering are intended for corporate development, including targeted acquisitions, scaling up R&D, accelerating its high-speed optical module and light source businesses, thereby enhancing competitive positioning.
- Market Reaction: Despite the positive implications of the financing plan, shares fell 3.11% in pre-market trading, indicating a cautious market sentiment regarding the offering.
See More
Valneva SE Withdraws Chikungunya Vaccine Applications, Shares Drop 7.7%
- Vaccine Withdrawal: Valneva SE has withdrawn its BLA and IND applications for the IXCHIQ Chikungunya vaccine due to an FDA suspension and review of new serious adverse events, leading to a 7.7% drop in pre-market trading to $9.29, indicating market concerns over its product prospects.
- Market Decline: U.S. stock futures are broadly lower, with Dow futures falling around 700 points, reflecting investor caution regarding economic outlook, which may impact overall market sentiment and exacerbate volatility in other stocks.
- Other Stock Movements: Shares of Rezolve AI PLC and POET Technologies Inc fell 15% and 11.2% respectively in pre-market trading, indicating widespread investor apprehension towards tech stocks, potentially prompting a reassessment of risk appetite.
- Tesla Update: Tesla's stock fell 2.7% to $425.75 in pre-market trading, despite CEO Elon Musk confirming that vehicles equipped with the AI4 chip will achieve unsupervised autonomous driving, suggesting insufficient market confidence in the electric vehicle sector.
See More
Poet Technologies Issues 20.7 Million Shares to Raise $150 Million, Stock Plummets 17%
- Capital Raising Announcement: Poet Technologies revealed plans to issue 20.7 million shares, aiming to raise approximately $150 million, which led to a 17% drop in stock price, indicating strong market discontent with the financing effort.
- Significant Stock Impact: The share price is set at about $7.25, resulting in a market cap reduction to approximately $759 million, reflecting investor concerns over dilution of existing shares.
- Clear Use of Proceeds: The company intends to allocate the raised funds to enhance research and development as well as the development of high-speed optical modules and light sources, particularly for applications in artificial intelligence infrastructure, demonstrating its focus on future market opportunities.
- Market Reaction Analysis: Although the financing may dilute shares, analysts believe that investing in AI technology holds substantial potential, possibly presenting a buying opportunity for long-term investors in Poet as the sector continues to grow.
See More
Abbott Laboratories (ABT) Reports Q4 Sales Below Expectations, Stock Drops 7%
- Sales Performance Miss: Abbott Laboratories reported Q4 2025 sales of $11.46 billion, slightly below the consensus estimate of $11.80 billion, with a 4.4% increase in sales but only 3% organic growth, indicating competitive pressure in the market.
- Earnings Outlook Disappointment: Although adjusted earnings per share of $1.50 met Wall Street expectations, the overall performance failed to boost investor confidence, resulting in a stock drop of over 7% on Thursday, reflecting concerns about future growth.
- Market Reaction Intense: Following Abbott's earnings report, the significant stock decline illustrates investor pessimism regarding the company's future performance, which may impact its market position in the MedTech sector.
- Industry Impact Significant: Abbott's disappointing results could trigger a ripple effect across the MedTech industry, prompting investors to reassess the financial health of other related companies, potentially leading to overall valuation fluctuations in the sector.
See More
Poet Technologies Plans $150 Million Offering to Accelerate R&D and Acquisitions
- Clear Use of Proceeds: Poet Technologies plans to utilize the $150 million from its registered direct offering for targeted acquisitions, scaling up R&D, and accelerating its high-speed optical module and light source businesses, aiming to enhance overall operational capacity and market competitiveness.
- Offering Details Disclosed: The company will sell over 20 million common shares to institutional investors, with the offering expected to close around January 23, 2026, reflecting confidence in future growth prospects.
- Mixed Market Reaction: Despite a more than 13% drop in POET's stock price following the announcement, retail sentiment on Stocktwits remains 'extremely bullish', with investors believing the offering will strengthen the company's cash flow and market position.
- Potential Risk Warning: Some users caution that the offering may lead to share dilution, noting that POET's stock fell by 50% after the last issuance, prompting investors to carefully assess the associated risks and rewards.
See More
POET Technologies Announces Direct Offering of 20.7M Shares, Expected to Raise $150M
- Funding Plan: POET Technologies has entered into securities purchase agreements with institutional investors to sell 20,689,656 common shares, expected to raise approximately $150 million, which will be utilized for corporate development and targeted acquisitions to enhance R&D capabilities.
- Market Reaction: Despite the Nasdaq gaining 1.01%, POET's stock fell 7.77% to $7.72, indicating a negative market response to the offering news, which may impact short-term investor confidence.
- Technical Indicators: The stock is currently trading 4.2% above its 20-day simple moving average and 22% above its 100-day moving average, indicating a strong long-term trend, with shares up 53.58% over the past 12 months, approaching 52-week highs.
- Earnings Expectations: Investors are looking forward to the upcoming earnings report, with an EPS estimate of a loss of 6 cents (an improvement from a loss of 48 cents YoY) and a revenue estimate of $0.62 million (up from $0.03 million YoY), indicating potential for earnings improvement.
See More
POET Technologies Prices $150M Direct Offering Amid 3.11% Pre-Market Drop
- Offering Size: POET Technologies announced a registered direct offering priced at $150 million, involving 20,689,656 shares of common stock, highlighting the company's ability to raise capital in the market.
- Investor Agreements: The company has entered into securities purchase agreements with institutional investors, with the offering expected to close around January 23, 2026, providing essential funding for future growth.
- Use of Proceeds: The net proceeds from this offering are intended for corporate development, including targeted acquisitions, scaling up R&D, accelerating its high-speed optical module and light source businesses, thereby enhancing competitive positioning.
- Market Reaction: Despite the positive implications of the financing plan, shares fell 3.11% in pre-market trading, indicating a cautious market sentiment regarding the offering.
See More
Valneva SE Withdraws Chikungunya Vaccine Applications, Shares Drop 7.7%
- Vaccine Withdrawal: Valneva SE has withdrawn its BLA and IND applications for the IXCHIQ Chikungunya vaccine due to an FDA suspension and review of new serious adverse events, leading to a 7.7% drop in pre-market trading to $9.29, indicating market concerns over its product prospects.
- Market Decline: U.S. stock futures are broadly lower, with Dow futures falling around 700 points, reflecting investor caution regarding economic outlook, which may impact overall market sentiment and exacerbate volatility in other stocks.
- Other Stock Movements: Shares of Rezolve AI PLC and POET Technologies Inc fell 15% and 11.2% respectively in pre-market trading, indicating widespread investor apprehension towards tech stocks, potentially prompting a reassessment of risk appetite.
- Tesla Update: Tesla's stock fell 2.7% to $425.75 in pre-market trading, despite CEO Elon Musk confirming that vehicles equipped with the AI4 chip will achieve unsupervised autonomous driving, suggesting insufficient market confidence in the electric vehicle sector.
See More
